In this free webinar, learn about the new revisions related to 2022 ISO 11608 Parts 1-6 and the impact to pharmaceutical manufacturers. Attendees will recognize what phase of development is ideal under the new requirements. Attendees will also understand critical decision points and common missteps between device development and pharmaceutical manufacturers. The featured speakers will discuss best practices to successfully incorporate 2022 ISO 11608 methodology to mitigate risk and accelerate time to market in combination product development.
TORONTO, Aug. 29, 2022 /PRNewswire-PRWeb/ -- As the regulatory guidance and expectations around drug device combination products continues to develop, the agreed upon approaches to demonstrate safety and effectiveness likewise develops. One long awaited significant change involves the 2022 revision of ISO 11608, Needle-based injection systems for medical use — Requirements and test methods: Parts 1-5, along with the addition of Part 6, which is specific to On-Body Delivery Systems.
This new standard is a result of collaboration between industry and global regulatory authorities via the ISO Technical Committee 84 working groups. The 2022 versions of ISO 11608 Parts 1-6 were recognized by the US Food and Drug Administration (FDA) as consensus standards for on-body injectors (Product Code QLF) on May 30, 2022. The 2022 revisions were created in part to satisfy the increase in wearable injection devices, where no existing standard directly applied.
Although the prior versions of the ISO 11608 series of standards (Parts 1-5) have been in place, the expectation from the FDA is that compliance to the 2022 revisions should occur prior to July 9, 2023, and compliance with Part 6 is in effect as of May 30, 2022. Therefore, medicinal product manufacturers should work with their device counterparts on a plan for implementation to ensure timely global regulatory compliance. Understanding the impact of these new revisions on development timelines is vital as wearable injectors become more desirable by patients.
The featured speakers will cover highlights of the major updates, including the impact to both device and pharmaceutical manufacturers, and how holistic implementation strategies can decrease risk and shorten time to market. In addition, the speakers will showcase interactive best practices examples that provide real-world methods for aligning drug and device development pathways for a combination product-centric approach.
Register to learn how the new revisions and additions to the 2022 ISO 11608 series impacts the wearable injectors market.
Join Carolyn Dorgan, Principal Consulting Engineer - Regulatory Affairs, Suttons Creek, Inc.; and Lauren Orme, Director, Regulatory Policy and Intelligence West Pharmaceutical Services, Inc., for the live webinar on Tuesday, September 20, 2022, at 11am EST (4pm BST/UK).
For more information, or to register for this event, visit ISO 11608: Best Practices to De-Risk & Shorten Time to Market for Wearable Injectors.
ABOUT XTALKS
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
To learn more about Xtalks visit http://xtalks.com
For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/
Contact:
Vera Kovacevic
Tel: +1 (416) 977-6555 x371
Email: [email protected]
Media Contact
Vera Kovacevic, Xtalks, +1 (416) 977-6555 x371, [email protected]
SOURCE Xtalks
Share this article